A Study of Pharmacogenomics (PGx) Results and Clinical Data of Patients in the Palliative Medicine Clinic to Assess Current and Future Therapeutic Relevance
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Scottsdale/Phoenix, Arizona: 17-007275
Sponsor Protocol Number: 17-007275
About this study
The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- A Mayo Clinic patient newly referred to the Palliative Medicine Clinic for malignancy-associated symptom management, including but not limited to analgesia, nausea control, anxiolysis, and mood disturbances, seeking clinical information from emerging PGx testing technologies available in CLIA/CAP laboratories.
- Patient age 18 or above.
- Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.
- Patient is willing to engage in a medication assessment as part of their clinical visit preparation (when needed).
Exclusion Criteria
- Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
- Patient’s referred to the Palliative Medicine Clinic primarily for symptoms related to non-malignant comorbidities.
- Patient’s previously established within the Palliative Medicine Clinic who receive ongoing Palliative Medicine services.
- Patient’s referred to the Palliative Medicine Clinic without active symptoms requiring pharmacologic intervention.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Mark Edwin, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available